Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia’s PBS Lists Four Adalimumab Biosimilars

‘A-Flag’ Allows Substitution For Humira As Well As Between Biosimilars

Executive Summary

Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.

You may also be interested in...



Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie

AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.

Organon Completes Spin-Out From Merck With Five Biosimilars

With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.

What’s Next? Five Things To Look Out For In April

In April, four Humira (adalimumab) biosimilars are to be listed on Australia’s Pharmaceutical Benefits Scheme, while first-quarter financial reports will hit the market.

Related Content

Topics

UsernamePublicRestriction

Register

GB150788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel